EA202191763A1 - Бифункциональная молекула анти-pd-1/sirp - Google Patents

Бифункциональная молекула анти-pd-1/sirp

Info

Publication number
EA202191763A1
EA202191763A1 EA202191763A EA202191763A EA202191763A1 EA 202191763 A1 EA202191763 A1 EA 202191763A1 EA 202191763 A EA202191763 A EA 202191763A EA 202191763 A EA202191763 A EA 202191763A EA 202191763 A1 EA202191763 A1 EA 202191763A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sirp
molecule
bifunctional anti
bifunctional
antibody
Prior art date
Application number
EA202191763A
Other languages
English (en)
Inventor
Никола Пуарье
Каролин Мари
Ауроре Морелло
Кевин Бито
Original Assignee
Озе Иммьюнотерапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Озе Иммьюнотерапьютикс filed Critical Озе Иммьюнотерапьютикс
Publication of EA202191763A1 publication Critical patent/EA202191763A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к бифункциональной молекуле, содержащей анти-PD-1 антитело и SIRP; и к ее применению.
EA202191763A 2018-12-21 2019-12-17 Бифункциональная молекула анти-pd-1/sirp EA202191763A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306810 2018-12-21
PCT/EP2019/085785 WO2020127373A1 (en) 2018-12-21 2019-12-17 Bifunctional anti-pd-1/sirpa molecule

Publications (1)

Publication Number Publication Date
EA202191763A1 true EA202191763A1 (ru) 2022-03-10

Family

ID=65628505

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191763A EA202191763A1 (ru) 2018-12-21 2019-12-17 Бифункциональная молекула анти-pd-1/sirp

Country Status (14)

Country Link
US (1) US20220056135A1 (ru)
EP (1) EP3898676A1 (ru)
JP (1) JP2022514698A (ru)
KR (1) KR20210107062A (ru)
CN (1) CN113574067A (ru)
AU (1) AU2019409805A1 (ru)
BR (1) BR112021012040A2 (ru)
CA (1) CA3122914A1 (ru)
CL (1) CL2021001627A1 (ru)
EA (1) EA202191763A1 (ru)
IL (1) IL283992A (ru)
MX (1) MX2021007274A (ru)
SG (1) SG11202106251UA (ru)
WO (1) WO2020127373A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912879YA (en) 2016-12-09 2020-02-27 Alector Llc Anti-sirp-alpha antibodies and methods of use thereof
HRP20220605T1 (hr) 2017-01-25 2022-07-08 Ose Immunotherapeutics Postupak za proizvodnju stabilne emulzije za isporuku peptida
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
CN116063513A (zh) 2018-12-21 2023-05-05 Ose免疫疗法公司 人源化的抗人pd-1抗体
US20220025050A1 (en) * 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
CN114805592A (zh) * 2022-05-13 2022-07-29 南京吉盛澳玛生物医药有限公司 一种三特异性抗体的设计、制备及用途
WO2024028386A1 (en) * 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN115386550A (zh) * 2022-10-26 2022-11-25 成都诺医德医学检验实验室有限公司 一种评价免疫细胞抗癌有效性的方法
WO2024098939A1 (zh) * 2022-11-07 2024-05-16 北京伟德杰生物科技有限公司 双功能融合蛋白及其应用
CN115814091B (zh) * 2022-12-19 2024-08-09 中山大学 Cd43抑制剂在制备抗结直肠肿瘤药物中的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994004678A1 (en) 1992-08-21 1994-03-03 Casterman Cecile Immunoglobulins devoid of light chains
US5275285A (en) 1992-12-30 1994-01-04 Clegg Industries Business card holder with sound generating microchip
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP1366067B1 (en) 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック, インコーポレイテッド ヒト化抗TGF−β抗体
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
EP3797793A1 (en) 2014-04-18 2021-03-31 The Research Foundation of the State University of New York at Buffalo Humanized anti-tf-antigen antibodies
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
SG11201701189TA (en) 2014-08-15 2017-03-30 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
PL3328419T3 (pl) 2015-07-30 2021-12-27 Macrogenics, Inc. Cząsteczki wiążące pd-1 i sposoby ich zastosowania
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
JP7000660B2 (ja) 2016-01-20 2022-02-04 ザ スクリプス リサーチ インスティテュート Ror1抗体組成物及び関連の方法
SG11201806110QA (en) * 2016-01-21 2018-08-30 Univ Leland Stanford Junior Treatment of cancer with combinations of immunoregulatory agents
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
SG11201808465UA (en) * 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
CN107459578B (zh) * 2016-05-31 2021-11-26 泰州迈博太科药业有限公司 一种靶向cd47与pd-l1的双功能融合蛋白
KR20230114331A (ko) 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
KR102697723B1 (ko) 2017-01-18 2024-08-21 비스테라, 인크. 항체 분자-약물 접합체 및 이의 용도
CN108623689B (zh) * 2017-03-15 2020-10-16 宜明昂科生物医药技术(上海)有限公司 新型重组双功能融合蛋白及其制备方法和用途
WO2018176132A1 (en) * 2017-03-28 2018-10-04 Trillium Therapeutics Inc. Cd47 blockade therapy
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
JP7303802B2 (ja) 2017-09-23 2023-07-05 メモリアル スローン ケタリング キャンサー センター A33抗体組成物および放射性免疫療法におけるその使用方法
WO2019109357A1 (zh) * 2017-12-08 2019-06-13 杭州翰思生物医药有限公司 抗pd-1/cd47的双特异性抗体及其应用
JP7497292B2 (ja) 2018-03-05 2024-06-10 エタブリスモン フランセ ドュ サン 遺伝子組換え単鎖免疫グロブリン
US20220025050A1 (en) * 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1

Also Published As

Publication number Publication date
AU2019409805A1 (en) 2021-07-22
SG11202106251UA (en) 2021-07-29
US20220056135A1 (en) 2022-02-24
BR112021012040A2 (pt) 2021-11-03
WO2020127373A1 (en) 2020-06-25
CN113574067A (zh) 2021-10-29
CL2021001627A1 (es) 2022-01-07
EP3898676A1 (en) 2021-10-27
MX2021007274A (es) 2021-07-15
CA3122914A1 (en) 2020-06-25
JP2022514698A (ja) 2022-02-14
IL283992A (en) 2021-07-29
KR20210107062A (ko) 2021-08-31

Similar Documents

Publication Publication Date Title
EA202191763A1 (ru) Бифункциональная молекула анти-pd-1/sirp
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
EA202092435A2 (ru) Моноклональные антитела против bcma
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA202092847A1 (ru) Антитела к cd3 и их применение
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201992756A3 (ru) Антитела против cd48 и их конъюгаты
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo
EA201991876A1 (ru) Антитела против фактора d и их применения
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение